The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online

🎥 Rupert Bartsch of @CCC_Vienna talks on the ELEANOR interim analysis: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer

Watch: 👉http://ow.ly/uOVW50MsK6n👈

@SABCSSanAntonio #SABCS22 #BCSM #BreastCancer

The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?

🎥 Maartje Rohaan of @NKI_nl talks on optimizing TILs as a novel immunotherapy strategy in metastatic melanoma

Watch: 👉http://ow.ly/fo3h50MsK0i👈

@myESMO #ImmunoOnc #melanoma #melsm #skcsm

Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!

In high-grade #ovariancancer
The magnitude of benefit from olaparib may be related to the location of the mutation in BRCA1/2 🧬🧬
@Annals_Oncology @myESMO @OncoAlert @VJOncology @ESGO_society @acog @ASCO @agz_eriksson @IGCSociety @SGO_org @VukovicPetra
https://doi.org/10.1016/j.annonc.2022.11.003

Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

🎥 Rupert Bartsch of @CCC_Vienna talks on the ELEANOR interim analysis: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer

Watch: 👉http://ow.ly/uOVW50MsK6n👈

@SABCSSanAntonio #SABCS22 #BCSM #BreastCancer

The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?

🎥 Maartje Rohaan of @NKI_nl talks on optimizing TILs as a novel immunotherapy strategy in metastatic melanoma

Watch: 👉http://ow.ly/fo3h50MsK0i👈

@myESMO #ImmunoOnc #melanoma #melsm #skcsm

Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!

In high-grade #ovariancancer
The magnitude of benefit from olaparib may be related to the location of the mutation in BRCA1/2 🧬🧬
@Annals_Oncology @myESMO @OncoAlert @VJOncology @ESGO_society @acog @ASCO @agz_eriksson @IGCSociety @SGO_org @VukovicPetra
https://doi.org/10.1016/j.annonc.2022.11.003

Load More

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter